This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Brainsway Announces Final Results In Clinical Trial For Smoking Cessation In Chronic Obstructive Pulmonary Disease Patients

JERUSALEM, Jan. 24, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) ("Brainsway" or the "Company) is pleased to announce that it has received final results with respect to a clinical trial that was conducted at the Be'er Ya'akov Mental Health Center to assess the efficacy of the Company's Deep TMS device in inducing smoking cessation in chronic obstructive pulmonary disease ("COPD") patients using a specialized coil developed for this purpose.

A total of 115 patients participated in the study. The trial subjects were divided into three groups: a sham treatment group, a low-frequency real stimulation treatment group and a high-frequency real stimulation treatment group.  Half of the subjects in each group were exposed to cigarette cues designed to induce temporary cigarette craving prior to the start of each treatment session. Of these patients, 78 completed the treatment period (including 32 patients who received high-frequency treatment, 14 subjects who received low-frequency treatment and 32 subjects who received sham treatment).  The Company noted that, following an interim analysis, follow-up in the low-frequency group was discontinued as no improvement was observed in this group compared with the sham control group.

The primary outcome measure for therapeutic efficacy was the change in patients' cigarette consumption levels, as measured both by self-report and by urinary cotinine (a metabolite of nicotine) levels at the end of the treatment period, and again six months after the end of treatment using only self-report.

The results reveal a significant response (greater than 50% reduction in cigarette consumption) to treatment among approximately 81% of the high-frequency stimulation group subjects who were exposed to cigarette cues prior to treatment, compared to 12-29% of subjects in the other groups.  Approximately 44% of the subjects in the high-frequency stimulation group that were exposed to cigarette cues before each treatment session achieved total smoking cessation.  Approximately 84% of these subjects who achieved total smoking cessation at the end of the trial persisted in their abstinence six months after the end of the trial (as determined by self-report).  A similar trend was revealed in subjects' cigarette dependence levels, as measured by the Fagerström Test for Nicotine Dependence (FTND).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.26 -0.77%
FB $100.97 1.40%
GOOG $684.03 0.87%
TSLA $143.40 -3.30%
YHOO $27.10 1.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.39 -0.82 -0.04%
NASDAQ 4,283.28 +14.5170 0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs